S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
Log in

NASDAQ:PDSBPDS Biotechnology Stock Price, Forecast & News

$0.72
+0.05 (+7.21 %)
(As of 04/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.62
Now: $0.72
$0.74
50-Day Range
$0.65
MA: $1.00
$1.37
52-Week Range
$0.62
Now: $0.72
$9.45
Volume460,000 shs
Average Volume122,658 shs
Market Capitalization$4.16 million
P/E RatioN/A
Dividend YieldN/A
Beta2.64
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its lead product candidate is PDS0101, a monotherapy first line therapy for cervical intraepithelial neoplasia of cancer. In addition, the company develops PDS0102, which is in phase 2 clinical trial for treatment of prostate and breast cancers. Further, its pipeline product portfolio includes PDS0103 for treatment of colorectal, breast, ovarian, and lung cancers; and PDS 0104 for treatment of melanoma. Additionally, the company offers Versamune, a T-cell activating platform developed for immunotherapy approaches, such as checkpoint inhibitors, CAR-T cells and live-vector based vaccines, etc. The company has collaboration agreement with Merck and Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer. PDS Biotechnology Corporation was incorporated in 2009 and is based in Berkeley Heights, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PDSB
CUSIPN/A
CIKN/A
Phone800-208-3343

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.02 per share

Profitability

Net Income$-7,000,000.00

Miscellaneous

Employees14
Market Cap$4.16 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive PDSB News and Ratings via Email

Sign-up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.


PDS Biotechnology (NASDAQ:PDSB) Frequently Asked Questions

How has PDS Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

PDS Biotechnology's stock was trading at $0.9201 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PDSB stock has decreased by 21.7% and is now trading at $0.72. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PDS Biotechnology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PDS Biotechnology.

When is PDS Biotechnology's next earnings date?

PDS Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for PDS Biotechnology.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Corporation (NASDAQ:PDSB) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.28. View PDS Biotechnology's earnings history.

What price target have analysts set for PDSB?

3 brokerages have issued 1 year price objectives for PDS Biotechnology's stock. Their forecasts range from $5.45 to $10.00. On average, they anticipate PDS Biotechnology's share price to reach $7.48 in the next year. This suggests a possible upside of 939.4% from the stock's current price. View analysts' price targets for PDS Biotechnology.

Has PDS Biotechnology been receiving favorable news coverage?

Media headlines about PDSB stock have been trending very negative on Monday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. PDS Biotechnology earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutPDS Biotechnology.

Who are some of PDS Biotechnology's key competitors?

What other stocks do shareholders of PDS Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Las Vegas Sands (LVS), Gilead Sciences (GILD), Huntington Bancshares (HBAN), Methanex (MEOH), PacWest Bancorp (PACW), People's United Financial (PBCT), Pattern Energy Group (PEGI), Primo Water (PRMW), Walgreens Boots Alliance (WBA) and AbbVie (ABBV).

Who are PDS Biotechnology's key executives?

PDS Biotechnology's management team includes the following people:
  • Dr. Frank K. Bedu-Addo, Chief Exec. Officer, Pres & Director (Age 55)
  • Mr. Andrew Saik, CFO & Director (Age 50)
  • Dr. Gregory L. Conn, Chief Scientific Officer
  • Sir Richard Sykes, Exec. Director
  • Ms. Lauren V. Wood M.D., Chief Medical Officer

What is PDS Biotechnology's stock symbol?

PDS Biotechnology trades on the NASDAQ under the ticker symbol "PDSB."

How do I buy shares of PDS Biotechnology?

Shares of PDSB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PDS Biotechnology's stock price today?

One share of PDSB stock can currently be purchased for approximately $0.72.

How big of a company is PDS Biotechnology?

PDS Biotechnology has a market capitalization of $4.16 million. The company earns $-7,000,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. PDS Biotechnology employs 14 workers across the globe. View additional information about PDS Biotechnology.

What is PDS Biotechnology's official website?

The official website for PDS Biotechnology is http://www.pdsbiotech.com/.

How can I contact PDS Biotechnology?

PDS Biotechnology's mailing address is 303A College Road East, Princeton NJ, 08540. The company can be reached via phone at 800-208-3343 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel